Fig 2 - by Jens Panse (350046)

Effects of melatonin on the TGF-β1/Smad pathway and EMT in a PS/LPS-induced bladder fibrosis model in rats. by Yang Zhang (30734)

Fig 1 - by Jens Panse (350046)

Fig 5 - by Jens Panse (350046)

Intramammary rapamycin administration induces self-renewing cell properties. by Anna Kosenko (12908417)

Fig 3 - by Jens Panse (350046)

Decreased pMHC avidity and CD8β-independence for functional avidity of D^bNPN3A-primed T cells for D^bNP₃₆₆. by Sophie A. Valkenburg (176257)

Characteristics of JIA patients. by Yasmine Makhlouf (17409866)

“…Twelve studies published between 2003 and 2018 were analyzed, encompassing 1513 patients with a mean age of 11.4 years. Tumor necrosis factor alpha inhibitors were the predominant biologic agents used (75.8%), with a mean follow-up duration of 2 years post-biologic therapy initiation. …”

List of excluded articles. by Yasmine Makhlouf (17409866)

“…Twelve studies published between 2003 and 2018 were analyzed, encompassing 1513 patients with a mean age of 11.4 years. Tumor necrosis factor alpha inhibitors were the predominant biologic agents used (75.8%), with a mean follow-up duration of 2 years post-biologic therapy initiation. …”

<i>SLC2A2</i> is essential for liver differentiation in developing vertebrates by Yejin Kim (740789)

“…Data are presented as mean ± standard error of the mean (SEM). (G) Reduction in liver fluorescence intensity in zebrafish embryos following slc2a2 morpholino (MO) injection. …”

Modeling method used. by Claire Teillet (18986264)

“…Urban vegetation significantly influences larval presence, although higher vegetation index values correlate with a decreased probability of larval occurrence. Additionally, the combination of vegetation and urban structures plays a crucial role in determining the presence of <i>Ae. albopictus</i> larvae in public spaces, where small, organized urban objects and large patches of vegetation increase the likelihood of larval presence. …”

Kaplan-Meier survival curve in patients using HFNC according to WOB at 12-24 hours. by Edwin Aguirre-Milachay (15453672)

Kaplan-Meier survival curve in patients using HFNC according to iROX. by Edwin Aguirre-Milachay (15453672)

Kaplan-Meier survival curve in patients using HFNC according to age. by Edwin Aguirre-Milachay (15453672)

Kaplan-Meier survival curve in patients using HFNC according to hypertension. by Edwin Aguirre-Milachay (15453672)

Kaplan-Meier survival curve in patients using HFNC according to PaO2/FiO2. by Edwin Aguirre-Milachay (15453672)

Characteristics of COVID-19 patients using high-flow nasal cannula according to mortality. by Edwin Aguirre-Milachay (15453672)

Kaplan-Meier survival curve in patients using HFNC according to IMV. by Edwin Aguirre-Milachay (15453672)

Kaplan-Meier survival curve in patients using HFNC according to WOB at admission. by Edwin Aguirre-Milachay (15453672)

Parameters and times related to the use of high-flow nasal cannula and mechanical ventilation according to mortality in patients with COVID-19. by Edwin Aguirre-Milachay (15453672)